 |
49 Diseases |  |
53 Trials |
|
53 Trials |  |
326 News |  |
| «12345» |
- | Avastin (bevacizumab) / Roche, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial termination, Metastases: BEVATOMOX: 2nd-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 26, 2019
P2, N=83, Terminated, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting --> Terminated; too slow recruiting
- || oxaliplatin / Generic mfg., Tomudex (raltirexed) / Pfizer, AstraZeneca
Clinical, Journal: Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Dec 12, 2019
No grade 4 adverse events were observed. Raltitrexed plus oxaliplatin-based TACE led to high tumor response rate and promising PFS and OS, and was considered safe and tolerable in patients with unresectable HCC.
- || paclitaxel / Generic Mfg., cyclophosphamide intravenous / Generic Mfg.
Clinical, Journal: Validation and uncertainty estimation for trace amounts determination of 25 drugs used in hospital chemotherapy compounding units. (Pubmed Central) - Dec 2, 2019
Uncertainty associated to measurement of routine samples was evaluated. The multi-targeted method was specific and reliable and was successfully applied to wipe samples from hospital pharmacy chemotherapy compounding unit and to the determination of outside contamination of vials from pharmaceutical manufacturers.
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Clinical, Journal: Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases. (Pubmed Central) - Oct 18, 2019
No unexpected adverse events or toxic deaths were observed. TACE with raltitrexed plus oxaliplatin is feasible, clinically beneficial, and well tolerated with low-grade toxicity for colorectal cancer patients with liver metastases.
- Tomudex (raltirexed) / Pfizer, AstraZeneca
Identification of new subtype-specific treatment approaches by high-throughput drug screening in pancreatic ductal adenocarcinoma (A6) - Sep 30, 2019 - Abstract #DGHO2019DGHO_1469;
In the latter, two hits were exclusively present: a glucocorticoid steroid and Raltitrexed, an inhibitor of thymidylate synthase. Our data supports the notion that high-throughput drug screenings represent a powerful tool to elucidate new pathways involved in malignant diseases and to give the first steps towards the development of subtype-specific strategies for personalized treatment approaches in PDAC.
- Avastin (bevacizumab) / Roche, Tomudex (raltirexed) / Pfizer, AstraZeneca
Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_484;
P2
This trial will progress as planned.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- | fluconazole / Generic Mfg.
Journal: Synthesis, molecular docking and biological potentials of new 2-(4-(2-chloroacetyl) piperazin-1-yl)-N-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl)acetamide derivatives. (Pubmed Central) - Sep 15, 2019
The anticancer activity results indicated that compound 5 have good anticancer activity among the synthesized compounds but lower active than the standard drugs (5-fluorouracil and tomudex). Molecular docking study demonstrated that compounds 5 and 7 displayed the good docking score with better anticancer potency within the binding pocket and these compounds may be used as a lead for rational drug designing for the anticancer molecules.
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) (clinicaltrials.gov) - Sep 9, 2019
P2, N=100, Recruiting, Sponsor: Shenzhen People's Hospital
Molecular docking study demonstrated that compounds 5 and 7 displayed the good docking score with better anticancer potency within the binding pocket and these compounds may be used as a lead for rational drug designing for the anticancer molecules. Not yet recruiting --> Recruiting
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Clinical, P2 data, Journal: Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study. (Pubmed Central) - Aug 29, 2019
Not yet recruiting --> Recruiting Although stopped prematurely, this randomized trial provides evidence for the benefit and safety of HAI of a combination of raltitrexed and oxaliplatin in liver-only mCRC with chemoresistant disease.
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Clinical, Journal: Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. (Pubmed Central) - Jul 28, 2019
Although stopped prematurely, this randomized trial provides evidence for the benefit and safety of HAI of a combination of raltitrexed and oxaliplatin in liver-only mCRC with chemoresistant disease. A raltitrexed-based regimen is well-tolerated therapy with comparable efficacy to FPs in patients with GI malignancies with significant CV toxicities or risk factors.
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Journal: Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. (Pubmed Central) - Jul 26, 2019
A raltitrexed-based regimen is well-tolerated therapy with comparable efficacy to FPs in patients with GI malignancies with significant CV toxicities or risk factors. TACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Journal: Nucleoside analogue based supramolecular nanodrugs driven by molecular recognition for synergistic cancer therapy. (Pubmed Central) - Jun 26, 2019
In vitro studies exemplify how the clofarabine:raltitrexed nanoparticles could greatly improve synergistic combination effects by arresting more G1 phase of the cell cycle and reducing intracellular deoxynucleotides pools. More importantly, the nanodrugs increase blood retention half-life of the free drugs, improve the accumulation of drugs in tumor sites and promote the synergistic tumor suppression property in vivo.
- | Tomudex (raltirexed) / Pfizer, AstraZeneca
Journal: Multivalent nanoparticles for personalized theranostics based on tumor receptor distribution behavior. (Pubmed Central) - Apr 30, 2019
...In this study, a dual-acting agent raltitrexed was used as a ligand to target the folate receptor (FR)...Furthermore, in in vivo tumor inhibition and targeted magnetic resonance imaging (MRI) of KB tumors and another moderate FR expressing H22 tumor, similar results were obtained with the cell experiments. Overall, the optimizable treatment effect of Fe-PRn by modulating the ligand valency based on the overexpressing tumor receptor distribution behavior supports the potential of Fe-PRn as a nanomedicine for personalized theranostics.
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion date, Trial primary completion date: Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. (clinicaltrials.gov) - Feb 15, 2019
P4, N=202, Recruiting, Sponsor: The First Affiliated Hospital of Dalian Medical University
Overall, the optimizable treatment effect of Fe-PRn by modulating the ligand valency based on the overexpressing tumor receptor distribution behavior supports the potential of Fe-PRn as a nanomedicine for personalized theranostics. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2019 --> Aug 2020
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial: Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia (clinicaltrials.gov) - Jan 30, 2019
P2, N=50, Not yet recruiting, Sponsor: Fudan University
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) (clinicaltrials.gov) - Jan 22, 2019
P2, N=100, Not yet recruiting, Sponsor: Shenzhen People's Hospital
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open: Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus (clinicaltrials.gov) - Jan 9, 2019
P2, N=30, Recruiting, Sponsor: Huai'an First People's Hospital
Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2019 --> Aug 2020 Not yet recruiting --> Recruiting
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion, Enrollment change, Trial completion date: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Jul 16, 2018
P2, N=31, Completed, Sponsor: Centre Georges Francois Leclerc
Not yet recruiting --> Recruiting Recruiting --> Completed | N=80 --> 31 | Trial completion date: May 2020 --> Apr 2018
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial: Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus (clinicaltrials.gov) - Jul 12, 2018
P2, N=30, Not yet recruiting, Sponsor: Huai'an First People's Hospital
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Phase classification, Metastases: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) (clinicaltrials.gov) - Jun 19, 2018
P3, N=147, Recruiting, Sponsor: Fudan University
Recruiting --> Completed | N=80 --> 31 | Trial completion date: May 2020 --> Apr 2018 Phase classification: P2 --> P3
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open: Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. (clinicaltrials.gov) - Feb 6, 2018
P4, N=202, Recruiting, Sponsor: The First Affiliated Hospital of Dalian Medical University
Phase classification: P2 --> P3 Not yet recruiting --> Recruiting
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection (clinicaltrials.gov) - Jan 5, 2018
P2, N=48, Recruiting, Sponsor: Zhongnan Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Combination therapy, Metastases: A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 17, 2017
P2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Metastases: Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer (clinicaltrials.gov) - Oct 2, 2017
P2, N=82, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer (clinicaltrials.gov) - Sep 14, 2017
P2, N=46, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Dec 2017
- | Avastin (bevacizumab) / Roche, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment closed, Enrollment change, Metastases: BEVATOMOX: 2nd-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2017
P2, N=83, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Trial primary completion date: Mar 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=124 --> 83
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P4 trial: Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. (clinicaltrials.gov) - Jun 22, 2017
P4, N=202, Not yet recruiting, Sponsor: The First Affiliated Hospital of Dalian Medical University
- || Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial primary completion date: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Jun 20, 2017
P2, N=80, Recruiting, Sponsor: Centre Georges Francois Leclerc
Recruiting --> Active, not recruiting | N=124 --> 83 Trial primary completion date: Dec 2016 --> May 2019
- | Avastin (bevacizumab) / Roche, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 24, 2017
P2, N=100, Recruiting, Sponsor: Jiangsu Cancer Institute & Hospital
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Mar 19, 2017
P2, N=40, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Trial primary completion date, Metastases: Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases (clinicaltrials.gov) - Mar 13, 2017
P4, N=320, Recruiting, Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
Trial primary completion date: Dec 2016 --> May 2019 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2017
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Trial initiation date: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis (clinicaltrials.gov) - Mar 13, 2017
P3, N=360, Recruiting, Sponsor: Zhejiang University
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Feb 14, 2017
P2, N=100, Recruiting, Sponsor: China Medical University, China
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly (clinicaltrials.gov) - Dec 14, 2016
P2, N=68, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) (clinicaltrials.gov) - Nov 16, 2016
P2, N=147, Recruiting, Sponsor: Fudan University
- | Avastin (bevacizumab) / Roche, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 1, 2016
P2, N=37, Completed, Sponsor: Centre Hospitalier Universitaire de Besancon
- || Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial primary completion date: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Apr 25, 2016
P2, N=80, Recruiting, Sponsor: Centre Georges Francois Leclerc
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer (clinicaltrials.gov) - Mar 30, 2016
P2, N=18, Completed, Sponsor: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
- Tomudex (raltitrexed) / Pfizer, AstraZeneca
New trial: Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=200, Recruiting, Sponsor: Fudan University
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer (clinicaltrials.gov) - Dec 2, 2015
P2, N=82, Not yet recruiting, Sponsor: Fudan University
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer (clinicaltrials.gov) - Nov 30, 2015
P2, N=46, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Sep 2015 --> Mar 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion, Enrollment change, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Oct 9, 2015
P2, N=29, Completed, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Trial primary completion date: Sep 2015 --> Mar 2016 Recruiting --> Completed | N=80 --> 29
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin (clinicaltrials.gov) - Sep 29, 2015
P2, N=60, Recruiting, Sponsor: Hubei Cancer Hospital
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P4 trial: Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases (clinicaltrials.gov) - Sep 23, 2015
P4, N=100, Recruiting, Sponsor: Zhu Xu
- || Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P3 trial, Metastases: Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Jun 30, 2015
P3, N=120, Recruiting, Sponsor: Jiangsu Cancer Institute & Hospital
- |||||||||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P3 trial: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis (clinicaltrials.gov) - May 26, 2015
P3, N=360, Not yet recruiting, Sponsor: Zhejiang University
- ||||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Mar 3, 2015
P2, N=100, Recruiting, Sponsor: Fudan University
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=46, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Recruiting --> Completed | N=80 --> 29 Trial primary completion date: Dec 2013 --> Sep 2015
- |||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Dec 7, 2014
P2, N=80, Recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Dec 2013 --> Sep 2015 Suspended --> Recruiting
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial suspension, Trial primary completion date: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Sep 19, 2014
P2, N=80, Suspended, Sponsor: Centre Georges Francois Leclerc
Suspended --> Recruiting Recruiting --> Suspended | Trial primary completion date: Dec 2013 --> Dec 2015